Jakob Dupont - 16 Aug 2022 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Role
EVP, Head of R&D
Signature
/s/ David Tucker, Attorney-in-Fact for Jakob Dupont
Issuer symbol
ATRA
Transactions as of
16 Aug 2022
Net transactions value
-$20,760
Form type
4
Filing time
18 Aug 2022, 18:21:38 UTC
Previous filing
24 Aug 2023
Next filing
03 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATRA Common Stock Sale $20,760 -4,124 -2.5% $5.03 158,882 16 Aug 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units.
F2 The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee.